Progress in filovirus vaccine development: Evaluating the potential for clinical use

Darryl Falzarano, Thomas Geisbert, Heinz Feldmann

Research output: Contribution to journalArticle

72 Citations (Scopus)

Abstract

Marburg and Ebola viruses cause severe hemorrhagic fever in humans and nonhuman primates. Currently, there are no effective treatments and no licensed vaccines; although a number of vaccine platforms have proven successful in animal models. The ideal filovirus vaccine candidate should be able to provide rapid protection following a single immunization, have the potential to work postexposure and be cross-reactive or multivalent against all Marburg virus strains and all relevant Ebola virus species and strains. Currently, there are multiple platforms that have provided prophylactic protection in nonhuman primates, including DNA, recombinant adenovirus serotype 5, recombinant human parainfluenza virus 3 and virus-like particles. In addition, a single platform, recombinant vesicular stomatitis virus, has demonstrated both prophylactic and postexposure protection in nonhuman primates. These results demonstrate that achieving a vaccine that is protective against filoviruses is possible; the challenge now is to prove its safety and efficacy in order to obtain a vaccine that is ready for human use.

Original languageEnglish (US)
Pages (from-to)63-77
Number of pages15
JournalExpert Review of Vaccines
Volume10
Issue number1
DOIs
StatePublished - Jan 2011

Fingerprint

Vaccines
Marburgvirus
Ebolavirus
Primates
Human parainfluenza virus 3
Vesicular Stomatitis
Recombinant DNA
Adenoviridae
Virion
Immunization
Fever
Animal Models
Viruses
Safety
Therapeutics

Keywords

  • Ebola virus
  • filovirus
  • Marburg virus
  • postexposure
  • prophylactic
  • vaccine

ASJC Scopus subject areas

  • Immunology
  • Drug Discovery
  • Pharmacology
  • Molecular Medicine

Cite this

Progress in filovirus vaccine development : Evaluating the potential for clinical use. / Falzarano, Darryl; Geisbert, Thomas; Feldmann, Heinz.

In: Expert Review of Vaccines, Vol. 10, No. 1, 01.2011, p. 63-77.

Research output: Contribution to journalArticle

@article{7da3c35a2f084a73b49eb4fb4b4ec37a,
title = "Progress in filovirus vaccine development: Evaluating the potential for clinical use",
abstract = "Marburg and Ebola viruses cause severe hemorrhagic fever in humans and nonhuman primates. Currently, there are no effective treatments and no licensed vaccines; although a number of vaccine platforms have proven successful in animal models. The ideal filovirus vaccine candidate should be able to provide rapid protection following a single immunization, have the potential to work postexposure and be cross-reactive or multivalent against all Marburg virus strains and all relevant Ebola virus species and strains. Currently, there are multiple platforms that have provided prophylactic protection in nonhuman primates, including DNA, recombinant adenovirus serotype 5, recombinant human parainfluenza virus 3 and virus-like particles. In addition, a single platform, recombinant vesicular stomatitis virus, has demonstrated both prophylactic and postexposure protection in nonhuman primates. These results demonstrate that achieving a vaccine that is protective against filoviruses is possible; the challenge now is to prove its safety and efficacy in order to obtain a vaccine that is ready for human use.",
keywords = "Ebola virus, filovirus, Marburg virus, postexposure, prophylactic, vaccine",
author = "Darryl Falzarano and Thomas Geisbert and Heinz Feldmann",
year = "2011",
month = "1",
doi = "10.1586/erv.10.152",
language = "English (US)",
volume = "10",
pages = "63--77",
journal = "Expert Review of Vaccines",
issn = "1476-0584",
publisher = "Expert Reviews Ltd.",
number = "1",

}

TY - JOUR

T1 - Progress in filovirus vaccine development

T2 - Evaluating the potential for clinical use

AU - Falzarano, Darryl

AU - Geisbert, Thomas

AU - Feldmann, Heinz

PY - 2011/1

Y1 - 2011/1

N2 - Marburg and Ebola viruses cause severe hemorrhagic fever in humans and nonhuman primates. Currently, there are no effective treatments and no licensed vaccines; although a number of vaccine platforms have proven successful in animal models. The ideal filovirus vaccine candidate should be able to provide rapid protection following a single immunization, have the potential to work postexposure and be cross-reactive or multivalent against all Marburg virus strains and all relevant Ebola virus species and strains. Currently, there are multiple platforms that have provided prophylactic protection in nonhuman primates, including DNA, recombinant adenovirus serotype 5, recombinant human parainfluenza virus 3 and virus-like particles. In addition, a single platform, recombinant vesicular stomatitis virus, has demonstrated both prophylactic and postexposure protection in nonhuman primates. These results demonstrate that achieving a vaccine that is protective against filoviruses is possible; the challenge now is to prove its safety and efficacy in order to obtain a vaccine that is ready for human use.

AB - Marburg and Ebola viruses cause severe hemorrhagic fever in humans and nonhuman primates. Currently, there are no effective treatments and no licensed vaccines; although a number of vaccine platforms have proven successful in animal models. The ideal filovirus vaccine candidate should be able to provide rapid protection following a single immunization, have the potential to work postexposure and be cross-reactive or multivalent against all Marburg virus strains and all relevant Ebola virus species and strains. Currently, there are multiple platforms that have provided prophylactic protection in nonhuman primates, including DNA, recombinant adenovirus serotype 5, recombinant human parainfluenza virus 3 and virus-like particles. In addition, a single platform, recombinant vesicular stomatitis virus, has demonstrated both prophylactic and postexposure protection in nonhuman primates. These results demonstrate that achieving a vaccine that is protective against filoviruses is possible; the challenge now is to prove its safety and efficacy in order to obtain a vaccine that is ready for human use.

KW - Ebola virus

KW - filovirus

KW - Marburg virus

KW - postexposure

KW - prophylactic

KW - vaccine

UR - http://www.scopus.com/inward/record.url?scp=78650449257&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650449257&partnerID=8YFLogxK

U2 - 10.1586/erv.10.152

DO - 10.1586/erv.10.152

M3 - Article

C2 - 21162622

AN - SCOPUS:78650449257

VL - 10

SP - 63

EP - 77

JO - Expert Review of Vaccines

JF - Expert Review of Vaccines

SN - 1476-0584

IS - 1

ER -